ARS Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Laura Shawver, Ph.D.

ARS Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Laura Shawver, Ph.D.”): 45,149,811 for, 20,867,974 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class III directors, each to serve until the Company's 2029 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified, or until his or her earlier death, resigna…”
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 4,772,054 for, 1,274,279 withheld, 2 abstained.

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

Description as filed by funds: To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Phillip Schneider

ARS Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Phillip Schneider”): 38,474,013 for, 27,543,772 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class III directors, each to serve until the Company's 2029 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified, or until his or her earlier death, resigna…”
Support: 58% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 1,577,680 for, 4,468,652 withheld, 3 abstained.

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

Description as filed by funds: To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Saqib Islam, J.D.

ARS Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Saqib Islam, J.D.”): 51,588,419 for, 14,429,366 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class III directors, each to serve until the Company's 2029 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified, or until his or her earlier death, resigna…”
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 5,893,471 for, 152,863 withheld.

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.

ARS Pharmaceuticals, Inc.’s own tally for this item (“3. Advisory Vote on the Compensation of the Company's Named Executive Officers”): 57,290,450 for, 8,104,466 against — passed, per its Form 8-K filed June 25, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 29, 2026 (the "Proxy Statement").”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 53 managers: 3,504,666 for, 2,541,668 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 198 managers: 37,030,414 for, 7,383,005 against, 1,232 abstained, 319 not voted, 10,651 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 52 managers: 6,614 for, 6,031,670 1 year, 1,418 3 year, 9 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 189 managers: 53,547 for, 10,261 against, 319 not voted, 36,268,545 1 year, 9,325 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

ARS Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 79,465,541 for, 102,436 against — passed, per its Form 8-K filed June 25, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 6,046,334 for.

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.